June 10, 2024
IPGaia, Inc.
IPGaia Announce
Master Collaborative Research and Development Agreement with Tohoku University
IPGaia Inc. (President & CEO, Yasunori Yamaguchi, "IPG") has entered into a Master
Collaborative Research and Development Agreement ("this agreement") with Tohoku
University.
This agreement is intended to propose drug discovery seeds handled by Tohoku University
Hospital (Sendai, Miyagi Prefecture, Japan; Hospital Director: Hideo Harigae, “Tohoku
University Hospital”) ※1, regarding IPG platform for efficient generation of high-quality newdrugs. This agreement enables IPG to receive proposals for drug discovery seeds handled byTohoku University Hospital. IPG pursues the joint research program with Tohoku University
for identification and development of clinical development candidates with the goal oflicensing them to pharmaceutical companies. IPG is soliciting drug discovery seeds from awide range of research institutions, including global academia and pharmaceutical companies,
and is steadily expanding domestically and internationally to the nineth academia institution(Japan: 5 institutions, US: 3 institutions, Singapore: 1 institution), Tohoku University.
“It is our great pleasure and honor to have this agreement with Tohoku University, which isone of the top universities in Japan and has been selected by the Ministry of Education,Culture, Sports, Science and Technology as a candidate for recognition as Universities ofInternational Research Excellence that aim to become a world-leading research university.”
Yasu Yamaguchi, Ph.D., President and CEO of IPG states. “This enables IPG to access topromising drug discovery seeds and to create highly innovative medicines. IPG will continue
to contribute to solving the global social issues such as high healthcare costs and to extending
the healthy life expectancy.”※1

Tohoku University Hospital: Tohoku University Hospital is one of the national

university hospitals with the longest history in Japan. Under the philosophy of " Providing
advanced medical care with kindness”, the hospital provides advanced medical care safely, as
well as to its development and training. Additionally, while leveraging the strengths of being
part of a comprehensive university, the hospital actively adopts various innovative medical

technologies and fosters excellent medical professionals. This contributes to improving thequality of healthcare and solving medical challenges. In 2015, the hospital was designated by
the Ministry of Health, Labour and Welfare as a "Core Clinical Research Hospital" under theMedical Care Act. Centering on the "Clinical Research, Innovation and Education Center(CRIETO)" established within the hospital, it promotes international standard clinicalresearch, drug discovery, and medical device development in collaboration with various
enterprises, thereby contributing to the advancement of medicine and healthcare as a hub forclinical research.
[About IPG]
IPG was established on October 26, 2021, as a wholly owned subsidiary of the Healthcare
New Platform Fund where Whiz. Partners Inc. (Headquarters: Minato-ku, Tokyo; Presidentand CEO: Atsushi Matsumura) has been the general partner. IPG leverages the valuable drug
discovery research data and expertise of its comprehensive partnership agreement, Axceleadand Axcelead DDP, to select promising research seeds and projects. By collaborating among
the parties to build a next stage drug discovery platform, it would be possible to generate highquality innovative pharmaceuticals in a shorter period of time and lower cost. As for thepharmaceutical industry, the trend of the horizontal division of labor business model would
be more accelerating. IPG plays a role as a platformer for creating pre-clinical stage innovative
new medicines.
Contacts;IPGaia, Inc.
PR：Eri Yokota/Akiho Kamaguchi
Address：36F Atago Green Hills Mori Tower, 2-5-1 Atago, Minatoku, Tokyo Japan
Mobile：070-2485-4358
E-mail: contact@ip-g.com